CN103906515A - 治疗黏液表皮样癌的方法 - Google Patents

治疗黏液表皮样癌的方法 Download PDF

Info

Publication number
CN103906515A
CN103906515A CN201280047473.6A CN201280047473A CN103906515A CN 103906515 A CN103906515 A CN 103906515A CN 201280047473 A CN201280047473 A CN 201280047473A CN 103906515 A CN103906515 A CN 103906515A
Authority
CN
China
Prior art keywords
replace
replaced
compound
methyl
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280047473.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·D·格莱芬
吴丽姿
陈洁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CN103906515A publication Critical patent/CN103906515A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201280047473.6A 2011-09-30 2012-09-27 治疗黏液表皮样癌的方法 Pending CN103906515A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161541758P 2011-09-30 2011-09-30
US61/541,758 2011-09-30
US201261660377P 2012-06-15 2012-06-15
US61/660,377 2012-06-15
PCT/US2012/057480 WO2013049300A1 (en) 2011-09-30 2012-09-27 Method of treating mucoepidermoid carcinoma

Publications (1)

Publication Number Publication Date
CN103906515A true CN103906515A (zh) 2014-07-02

Family

ID=47016842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280047473.6A Pending CN103906515A (zh) 2011-09-30 2012-09-27 治疗黏液表皮样癌的方法

Country Status (12)

Country Link
US (1) US20140243396A1 (https=)
EP (1) EP2760445A1 (https=)
JP (1) JP2014532057A (https=)
KR (1) KR20140069038A (https=)
CN (1) CN103906515A (https=)
AU (1) AU2012316020A1 (https=)
BR (1) BR112014005730A2 (https=)
CA (1) CA2848065A1 (https=)
EA (1) EA201490725A1 (https=)
IN (1) IN2014CN02315A (https=)
MX (1) MX2014003873A (https=)
WO (1) WO2013049300A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986359A1 (en) 2015-05-20 2016-11-24 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2019107576A1 (ja) * 2017-11-30 2019-06-06 国立大学法人京都大学 始原生殖細胞／始原生殖細胞様細胞の維持増幅及び分化誘導方法
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN108578016B (zh) 2018-04-26 2020-09-08 赛诺医疗科学技术股份有限公司 一种经心尖植入式二尖瓣瓣膜装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541793A (zh) * 2006-11-20 2009-09-23 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
WO2010051043A1 (en) * 2008-11-03 2010-05-06 Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298864A1 (en) 2005-04-11 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for Treating Mild Cognitive Impairment
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2009052467A1 (en) * 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Methods of identifying pi-3-kinase inhibitor resistance
US20090192220A1 (en) * 2007-11-19 2009-07-30 Ore Pharmaceuticals Inc. Treatment for solid tumors
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer
JP2014503500A (ja) * 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101541793A (zh) * 2006-11-20 2009-09-23 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
WO2010051043A1 (en) * 2008-11-03 2010-05-06 Intellikine, Inc. Benzoxazole kinase inhibitors and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PETER G. SMITH等: "The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma", 《BLOOD》 *
PETER G. SMITH等: "The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT–dependent apoptosis in diffuse large B-cell lymphoma", 《BLOOD》, vol. 15, no. 1, 26 August 2004 (2004-08-26) *
刘弈等: "p70 S6K信号通路在黏液表皮样癌发生中的作用", 《口腔医学》 *
刘弈等: "p70 S6K信号通路在黏液表皮样癌发生中的作用", 《口腔医学》, vol. 29, no. 1, 31 January 2009 (2009-01-31) *

Also Published As

Publication number Publication date
MX2014003873A (es) 2014-05-28
WO2013049300A1 (en) 2013-04-04
JP2014532057A (ja) 2014-12-04
IN2014CN02315A (https=) 2015-06-19
CA2848065A1 (en) 2013-04-04
BR112014005730A2 (pt) 2017-03-28
AU2012316020A1 (en) 2013-05-09
EA201490725A1 (ru) 2014-11-28
KR20140069038A (ko) 2014-06-09
US20140243396A1 (en) 2014-08-28
EP2760445A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
AU2008251467B2 (en) Methods of treatment of skin ulcers
US8642602B2 (en) Method of inhibiting fibrogenesis and treating fibrotic disease
AU2007353454B2 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
CN103906515A (zh) 治疗黏液表皮样癌的方法
JP2016528873A (ja) 遺伝子発現を調節するための組成物及び方法
JP2009513494A (ja) Ｐｄｅ１０阻害剤としてのピロロジヒドロイソキノリン
CN109477090B (zh) 微小rna-143衍生物
CA3204756A1 (en) Compounds, compositions, and methods for treating or ameliorating nonalcoholic fatty liver disease and related diseases or disorders
US9987299B2 (en) Methods of improving RNAi in well-differentiated airway epithelia
US8263570B2 (en) Treating picornavirus infection by targeting MicroRNA miR-141
US20140294979A1 (en) Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression
US20230165873A1 (en) Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19
CA2588369A1 (en) Methods of treatment and prevention of metabolic bone diseases and disorders
WO2015193680A1 (en) Treatment
EP3007697B1 (en) Rac1 inhibitors for inducing bronchodilation
CA2588361A1 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
AU2014200542B2 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
CN119097627A (zh) 去泛素化酶抑制剂、核酸分子在制备治疗自身免疫障碍疾病的药物中的应用
WO2018157069A1 (en) Treatment of chronic hpv infection with the pan cdk inhibitor dinaciclib
WO2001047530A1 (en) A method of therapy and prophylaxis of inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140702